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Abstract 
Rationale: 5-HT receptor mechanisms have been suggested to mediate improvements 
in cognition in schizophrenia.  Aim: To investigate the involvement of 5-HT receptor 
mechanisms in sub-chronic PCP-induced reversal learning deficits in female rats, a 
task of relevance to schizophrenia.  Methods: Adult female hooded-Lister rats were 
trained to perform an operant reversal learning task and then received sub-chronic 
PCP (2 mg/kg) or vehicle i.p. twice daily for seven days, followed by 7-days washout.  
Rats then received an acute dose of the 5-HT7 receptor antagonist SB-269970A (1.0, 
3.0, 10.0 mg/kg; i.p.) or vehicle.  In experiment 2, PCP-treated rats received the 
selective 5-HT2C receptor antagonist, SB-243213A acutely (1.0, 3.0, 10.0 mg/kg; i.p.) 
or vehicle.  In experiment 3, PCP-treated rats received the 5-HT1A receptor partial 
agonist, buspirone (0.15625, 0.3125, 0.625 mg/kg, i.p.) in combination with the 
selective 5-HT1A receptor antagonist WAY-100635 (0.3, 1.0 mg/kg).  Results:  In all 
experiments sub-chronic PCP significantly impaired reversal phase performance 
(P<0.01-0.001), with no effect in the initial phase.  SB-269970A at 3.0 and 10.0 
mg/kg significantly improved the PCP-induced deficit (P<0.05).  SB-243213A also 
significantly attenuated the deficit at 10 mg/kg (P<0.05).  In experiment 3, buspirone 
attenuated the deficit with significant effects at 0.3125 mg/kg and 0.625 mg/kg 
(P<0.05).  WAY-100635 at 0.3 and 1.0 mg/kg produced a partial attenuation of 
buspirone’s effect as buspirone (0.3125 mg/kg) in the presence of WAY-100635 did 
not significantly reverse the PCP-induced deficit.  Conclusions:  These studies 
implicate the role of 5-HT7, 5-HT2C and 5-HT1A receptors in the improvement of 
cognitive dysfunction of relevance to schizophrenia.  
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 Introduction 
Sub-chronic phencyclidine (PCP) dosage regimes used to induce cognitive 
impairments in rats are believed to mimic those seen in schizophrenia (Javitt and 
Zukin, 1991; Jentsch and Roth, 1999).  In our laboratory, we have shown that PCP 
selectively impairs performance in reversal learning (Abdul-Monim et al., 2006; 2007; 
McLean et al., 2009), attentional set-shifting (McLean et al., 2008a) and novel object 
recognition (Grayson et al., 2007), importantly these tests are all of relevance to 
schizophrenia as highlighted by the MATRICS.ucla.edu initiative (Measurement and 
Treatment Research to Improve Cognition in Schizophrenia), and subsequently the 
TURNS.ucla.edu program (Treatment Units for Research on Neurocognition and 
Schizophrenia).  Our sub-chronic PCP dosing regime causes reduced density of 
parvalbumin-immunoreactive neurons in hippocampal regions (Abdul-Monim et al., 
2007) and levels of brain-derived neurotrophic factor mRNA (BDNF) in cortical 
regions (Snigdha et al., 2007) in rats.  Reductions in GABAergic interneurones in 
these areas have been found in post-mortem analysis from patients with schizophrenia 
(Benes et al., 1991; Benes and Berretta, 2001; Beasley et al., 2002; Zhang and 
Reynolds, 2002).  We have shown that atypical but not classical antipsychotics can 
reverse these cognitive deficits; however, in the clinic there is differing evidence for 
the efficacy of atypical antipsychotics in improving cognition with the CATIE study 
(Lieberman, 2006; Keefe et al., 2007) and the UK Cost Utility of the Latest 
Antipsychotic Drugs in Schizophrenia Study (CUtLASS; Jones et al., 2006; Lewis et 
al., 2006) suggesting that antipsychotics actually have a limited effect.  Cognitive 
dysfunction is a core characteristic of schizophrenia (Sullivan et al., 1994; Elvevag 
and Goldberg, 2000; Kuperberg and Heckers, 2000), occurring in 75-85% of patients 
(Reichenberg et al., 2006), and is becoming increasingly important as impaired 
cognition has been implicated in poor long-term functional outcome (Marder and 
Fenton, 2004) which can often persist when other symptoms may be improved with 
treatment (Gold et al., 1991; Heinrichs, 2005).  
The serotonergic system has been strongly implicated in the neurobiology of 
schizophrenia (for reviews see Meltzer, 1995; Roth et al., 2004).  In 1989 Meltzer 
defined atypical antipsychotic drugs as having higher affinity for 5-HT2A receptors 
than for D2 receptors.  5-HT2A receptor antagonists increase dopamine release in the 
prefrontal cortex (PFC; Ichikawa and Meltzer, 1990).  Although atypical 
antipsychotics such as risperidone and clozapine have high affinity for 5-HT2A 
receptors, it is unlikely that this mechanism alone is responsible for their 
antipsychotic action, as both have been shown to saturate 5-HT2 receptors at sub-
therapeutic doses (Kapur et al., 1999).  In our laboratory we plan to identify which 5-
HT receptors are important for cognition through use of selective compounds; as part 
of this work we have already shown that the 5-HT2A antagonist, M100.907, is 
efficacious in improving a sub-chronic PCP-induced deficit in reversal learning (Neill 
et al., 2008).   
5-HT7 receptors have been shown to have a role in learning and memory 
(Hedlund and Sutcliffe, 2004; Thomas and Hagan, 2004).  Risperidone and asenapine 
have high 5-HT7 receptor affinity (Shahid et al., 2009) and we have demonstrated 
efficacy of asenapine to reverse PCP-induced deficits in our models (Neill et al. 
submitted).  5-HT1A receptor agonism has been suggested to contribute to an atypical 
antipsychotic drug profile (Protais et al., 1994).  There are also interactions between 
5-HT2A, 5-HT2C and 5-HT1A receptors (Kapur and Remington, 1996; Meltzer, 1999).  
Antipsychotics which have been shown to be superior in improving cognition 
compared to typical antipsychotics in the clinic, including risperidone, olanzapine and 
ziprasidone (Harvey et al., 2004; Purdon et al., 2000), have high affinity for the 5-
HT2C receptor (see Miyamoto et al., 2005).  Furthermore, the 5-HT2C antagonist, SB 
242084, has recently been shown to improve serial spatial reversal learning 
(Boulougouris et al., 2008), supporting a role for 5-HT2C receptors in cognition.   
The aim of this study was to elucidate the 5-HT receptor mechanisms involved 
in the PCP-induced reversal learning deficit; by using selective compounds we also 
intend to further enhance the understanding of the mechanism of efficacy for current 
atypical antipsychotics.  Although the 5-HT6 receptor is a topical target for 
schizophrenia, this will not be addressed in this manuscript as we have previously 
shown that a selective 5-HT6 receptor antagonist can successfully reverse the PCP-
induced deficit in our laboratory (Neill et al., 2008).  Experiments were carried out 
using the partial 5-HT1A receptor agonist, buspirone, alone and in combination with 
the selective 5-HT1A receptor antagonist, WAY-100635.  We also investigated the 
effect of the selective 5-HT2C receptor antagonist, SB-243213A, and the 5-HT7 
receptor antagonist SB-269970A.  
 
Materials and Methods 
Subjects and housing conditions 
Two cohorts of fifty female hooded-Lister rats (Harlan, UK) housed in groups of four 
to five were used as subjects.  Animals initially weighing 200-220 g were maintained 
under standard laboratory conditions at a temperature of 21°C (±2°C) and humidity of 
40–50%.  They were maintained on a 12-h light/dark cycle (lights on at 07.00 hours), 
training and testing was carried out between 08.30 and 16.30.  Prior to operant 
training and testing, rats were gradually food deprived to approximately 90% of free-
feeding body weight; reduced body weight was maintained by restricting the amount 
of food (standard laboratory chow, Special Diet Services, Essex, UK) given to each 
rat per day (12 g/day). The availability of water was not restricted.  Experiments were 
conducted in accordance with the Animals (Scientific Procedures) Act UK (1986), 
and approved by the University of Bradford ethical review process. 
 
Apparatus 
All rats were tested in one of eight operant chambers (constructed in-house).  Each 
chamber (29×30×30 cm) consisted of Plexiglas walls and ceiling, and a metal grid 
floor over sawdust.  A hinged Plexiglas panel (6×6 cm) provided access to a food 
hopper containing food pellets (45 mg Noyes pellets, Sandown Scientific, UK).  Two 
retractable levers (4×2 cm) were positioned on either side of the food hopper.  A light 
emitting diode (LED) was positioned centrally above each lever and a house light was 
located in the ceiling of each chamber.  The chambers were placed individually within 
ventilated sound-attenuating hardboard boxes (69×38×42 cm) containing a Perspex 
window to allow viewing.  A small fan was built into each chamber to mask external 
noise.  Each animal was tested in the same operant chamber throughout the study. All 
boxes were controlled by Med-PC software (Version 2.0 for DOS or Med-PC for 
Windows, Med Associates, Inc. Lafayette, Indiana).  Programmes were written using 
Medstate notation. 
 
Operant training sessions 
Following habituation to the operant chambers, rats were trained to respond for food 
on a fixed ratio 1 (FR1) schedule of reinforcement with both levers active, as 
previously described in detail (Abdul-Monim et al., 2003; 2006).  When responding 
stabilised, rats were trained to press either the left or right lever for food delivery 
according to a visual cue (LED on or off).  The position of the LED to the active lever 
did not change within the session.  The experimental session was terminated 
following a total of 128 lever presses, which took approximately 30 minutes.  Rats 
were trained once daily and this was repeated until rats had reached criterion, i.e. 90% 
correct responding for three consecutive days, this took approximately 6 weeks of 
training, 5 days per week. 
 
Reversal-learning task 
The day before each reversal task session, a full 30-min operant training session (as 
described above) was conducted in order to ensure stable responding, i.e. 90% correct 
responding.  The reversal-learning session involved animals being first exposed to a 
5-min period during which the active lever was the same as on the previous operant 
training day.  During this period, responses on both correct and incorrect levers were 
recorded.  This part of the session was termed the initial phase.  This was followed by 
a 2-min time-out period, which was signalled by the house light being turned off. In 
the subsequent 5-min period, the active lever was reversed.  Responses made on the 
correct and incorrect levers were again recorded.  This second period was termed the 
reversal phase.  Animals undertook several of these reversal-learning sessions before 
beginning the drug studies in order to ensure that they attained a stable level of 
performance, i.e. 90% correct responding and at least 25 lever presses in total, in both 
the initial and reversal phases of the task.  This process took approximately 6 weeks 
of training, 5 days per week.  In both training phases all rats achieved training 
criterion within 5 days of each other. 
  
Experimental design—drug studies 
Eight to 10 trained rats were used per group in the drug studies.  Rats were tested on a 
cycle of 4 days (previously described by Idris et al., 2005, see table 1).  On day 1, 
each animal had a 30-min operant training session. The following day animals 
received the appropriate drug(s) and undertook a reversal-learning test session. On 
day 3 and day 4, each animal underwent a further operant training session and 
reversal test session, respectively, in order to ensure that responding was regained 
after the drug treatment.  In the current experiments normal responding was restored 
following each drug treatment, if performance was not fully restored, the cycle shown 
in table 1 would be repeated with no drug treatments until baseline performance in the 
reversal test was restored. 
A total of four drug experiments were carried out using two cohorts of 50 rats. 
The first cohort was only used for the first drug experiment (SB-269970A). The 
second cohort took part in the other three experiments.  The experiment with 
buspirone and WAY-100635 was carried out over 2 experiments; subsequently the 
data were pooled giving 20 rats in the vehicle and PCP groups.  The drug treatment 
given to each rat (and within each home cage) over the course of these experiments 
was randomised. Every effort was made to keep the number of drug and vehicle 
treatments equivalent among animals and to randomise the order of treatments.  The 
order of procedures and drug treatments are shown as weeks post training in table 2. 
 
Drugs 
The doses of buspirone were selected based on previous dose-response experiments 
carried out in this reversal learning task (McLean et al., 2008b).  WAY-100635 has 
selective 5-HT1A receptor antagonist activity at the doses used in this study (Prinssen 
et al., 1999).  The doses of SB-269970A were selected based on pharmacokinetic 
analysis (Hagan et al., 2000), doses of SB-243213A (5-methyl-1-[[2-[92-methyl-3-
pyridyl0oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindone hydrochloride) were 
selected based on effects observed in a study by Wood et al., (2001).   
For both cohorts the study design involved five groups (n = 10 per group 
initially); following stable performance in the reversal learning task, rats were given 
either 2.0 mg/kg PCP (n = 40) or vehicle (0.9% saline; n = 10) by the intraperitoneal 
(i.p.) route twice daily for seven days.  Dosing with sub-chronic PCP or vehicle was 
followed by a washout period of a further seven days.  PCP hydrochloride (Sigma, 
UK) was dissolved in 0.9% saline.  This dosage regime has proved to be very 
successful in our laboratory in producing robust reversal learning (Abdul-Monim et 
al., 2006; 2007; McLean et al., 2009) object recognition (Grayson et al., 2007) and 
attentional set-shifting deficits (McLean et al., 2008a), and social behaviour deficits 
(Snigdha and Neill, 2008a; 2008b).  In these experiments we have used female rats 
and we have previously shown that the stage of oestrous cycle does not affect reversal 
learning performance (McLean et al., 2009).  We have also found females to be better 
at novel object recognition compared with males (Sutcliffe et al., 2007), and we have 
demonstrated that female rats are more sensitive to our PCP dosage regime in 
attentional set-shifting (McLean et al., 2007).  
SB-269970A (supplied by GSK, Harlow, UK) was prepared in distilled water 
and given in a volume of 1 ml/kg via the i.p. route, and was administered 45min 
before testing.   Buspirone hydrochloride (Sigma, UK) and WAY-100635 (Sigma, UK) 
were dissolved in 0.9% saline and given in 1 ml/kg volume via the i.p. route; 
buspirone was administered 30 min prior to testing and WAY-100635 was 
administered 30 min prior to buspirone.  In the experiment with WAY-100635 alone, 
doses of 0.3 and 1.0 mg/kg were administered 30 min prior to testing.  SB-243213A 
(supplied by GSK, Harlow, UK) was dissolved in vehicle containing cyclodextrin 
(8% by weight) plus 25mM citric acid, and was administered 30 min prior to testing 
via the i.p. route in a volume of 2 ml/kg.   
 
Data and statistical analysis 
Data for percentage correct responding was calculated using the number of presses on 
the correct lever divided by the total number of presses multiplied by 100.  The 
percent correct data was then arcsine transformed and analysed by a one-way 
ANOVA followed by post-hoc Dunnett’s t-test comparing drug treatment to the PCP-
treated group.  The total number of lever presses was calculated by adding the correct 
and incorrect presses together within the 5-min test session, this was used to assess 
whether drugs had caused any sedation or motor impairments. 
 
Results 
Experiment 1 – Effect of SB-269970A 
There was no significant effect on total lever pressing in the initial or reversal phases, 
suggesting that neither locomotor capacity nor motivation were affected (fig 1a).  For 
percent correct responding, a paired t-test showed a significant reduction in 
responding in the reversal phase compared to the initial phase in the PCP-treated 
group (P<0.001).  A one-way ANOVA in the reversal phase showed a significant 
effect of treatment (F4,43 = 5.94, P<0.01).  Post-hoc analysis revealed that SB-
269970A at 3 mg/kg and 10 mg/kg significantly (P<0.01) improved the PCP-induced 
deficit (fig 1b).   
 
Experiment 2 – Effect of SB-243213A 
There was no significant effect on total lever pressing in the initial or reversal phases, 
suggesting that neither locomotor capacity nor motivation were affected (fig 2a).  For 
percent correct responding, a paired t-test showed a significant reduction in correct 
responding in the reversal phase compared to the initial phase in the PCP-treated 
group (P<0.001), 1.0 mg/kg treated group (P<0.01) and 3.0 mg/kg treated group 
(P<0.001).  A one-way ANOVA in the reversal phase showed a significant effect of 
treatment (F4,49 = 7.27, P<0.001).  Post-hoc analysis revealed that SB-243213A at 10 
mg/kg significantly (P<0.05) improved the PCP-induced deficit (fig 2b).   
 
Experiment 3 – Effect of buspirone and WAY-100635 
There was no significant effect on total lever pressing in the initial or reversal phases 
following any acute drug treatment (fig 3a).  For percent correct responding, a paired 
t-test showed a significant reduction in correct responding in the reversal phase 
compared to the initial phase in the PCP-treated group (P<0.001), and in the PCP 
animals treated acutely with buspirone at 0.15625 mg/kg (P<0.05).  A one-way 
ANOVA in the reversal phase showed a significant effect of treatment (F6,75 = 5.77, 
P<0.001).  Post-hoc analysis revealed that PCP rats treated with buspirone at 0.3125 
and 0.625 mg/kg had significantly improved reversal learning compared to the PCP 
alone group (P<0.01; fig 3b).  The lower dose of 0.156 had no effect as indicated by 
significant reduction in responding compared with the initial phase.  Pre-treatment 
with WAY-100635 (0.3 and 1.0 mg/kg) partially antagonised the effect of buspirone 
(0.3125 mg/kg) such that buspirone in the presence of WAY-100635 (0.3 and 1.0 
mg/kg) did not significantly reverse the PCP-induced deficit (P=0.208 and P=0.082 
respectively).  However, there was no significant difference between buspirone alone 
(0.3125 mg/kg) and buspirone (0.3125 mg/kg) in the presence of WAY-100635 at 0.3 
mg/kg (P=0.451) and 1.0 mg/kg (P=0.712).   
 
Experiment 4 – Effect of WAY-100635 alone 
There was no significant effect on total lever pressing in the initial or reversal phases 
following treatment with WAY-100635 (fig 4a).  For percent correct responding, a 
paired t-test showed a significant reduction in performance of the reversal phase 
compared with the initial phase in the PCP-group (P<0.001), and both WAY-1000635 
treated groups (P<0.05, fig 4b). A one-way ANOVA in the reversal phase showed a 
significant effect of treatment interaction (F3,33 = 4.57, P<0.01).  Post-hoc analysis 
revealed WAY-100635 at 0.3 and 1.0 mg/kg did not significantly improve correct 
responding compared to PCP alone in the reversal phase (P=0.54 and P=0.42 
respectively).   
 
Discussion 
The current experiments utilised an operant reversal learning paradigm to examine the 
effects of selective 5-HT receptor compounds in order to establish which specific 
receptors were involved in cognitive enhancement for identification of novel targets 
and to provide improved understanding of the receptor mechanisms involved in 
existing antipsychotic therapies.  The principal findings show that the 5-HT7 receptor 
antagonist, SB-269970A, the 5-HT2C receptor antagonist SB-243213A and the 5-
HT1A receptor partial agonist buspirone attenuated the sub-chronic PCP-induced 
deficit in the reversal phase of the task. 
 
Reversal learning task and PCP-induced disruption 
Successful reversal learning ability relies on the intact function of the prefrontal 
cortex.  It has been shown more specifically that lesions of the orbital prefrontal 
cortex impair reversal learning ability (McAlonan and Brown, 2003; Tait and Brown, 
2007).  The prefrontal cortex is believed to be important for effective functioning in 
tests such as the WCST and impaired performance is seen in patients with 
schizophrenia (Haut et al., 1996; Pantelis et al., 1999).  It has been shown that 5-HT 
receptor antagonists could have antipsychotic efficacy via increasing release of 
dopamine in the PFC (Ichikawa and Meltzer, 1990; Di Matteo et al., 2001).  PCP has 
been shown to affect dopamine levels within the PFC and nucleus accumbens and 
reduced dopamine within the PFC is thought to mediate both negative and cognitive 
symptoms of schizophrenia (Jentsch and Roth 1999); thus, activity at 5-HT receptors 
may indirectly improve PCP-induced deficits via modulation of dopamine release in 
the PFC.  In a recent novel object recognition study we have shown that sub-chronic 
PCP impairs the ability of rats to recognise the familiar object in retention (and hence 
discriminate between the novel and familiar object) and also abolishes prefrontal 
dopamine release which is increased in control rats selectively in the retention trial 
(Snigdha et al., 2008c).  Moreover, we have recently shown that the dopamine D1 
receptor agonist, SKF-38393, improves sub-chronic PCP-induced deficits in reversal 
learning and novel object recognition (McLean et al., 2009).  These findings strongly 
support a role for prefrontal dopamine working through a D1 receptor mechanism to 
improve cognition of relevance to schizophrenia. 
The present results show that vehicle-treated rats can be trained to an 
equivalent level of accuracy in both the initial and reversal phases of the task.  
Following treatment with sub-chronic PCP, rats demonstrated a robust and replicable 
impairment which is selective for the reversal phase.  We have shown this effect 
several times now (Abdul-Monim et al., 2006; 2007; Neill et al., submitted; McLean 
et al., 2009) and this effect is also observed following acute treatment with PCP and 
d-amphetamine (Abdul-Monim et al., 2003; Idris et al,. 2005). 
 
Effect of SB-269970A 
SB-269970A is a selective 5-HT7 receptor antagonist (Varnäs et al., 2004).  5-HT7 
receptors are located in the thalamus, hypothalamus and amygdala in addition to 
limbic and cortical regions (Thomas et al., 2002; Varnäs et al., 2004).  Activity at 5-
HT7 receptors has been suggested to have a strong role in cognitive dysfunction 
(Hedlund and Sutcliffe, 2004; Thomas and Hagan, 2004).  The 5-HT7 receptor is a 
potential target of relevance to schizophrenia as many atypical antipsychotics such as 
risperidone and ziprasidone have affinity for this receptor (Roth et al., 1994; Siegfried 
et al., 2005), and some e.g. clozapine have significant inverse agonist activity (Mahe 
et al., 2004).  The results of experiment 1 with SB-269970A showed that 3.0 and 10.0 
mg/kg of SB-269970A significantly ameliorated the PCP-induced deficit.  There were 
no effects on the initial phase of the task or on total lever pressing.   
SB-269970 (at 3.0 and 10.0 mg/kg) has been previously shown to reverse 
cognitive impairments induced by scopolamine and dizocilpine (Meneses, 2004).  In a 
recent study by Galici and co-workers (2008) SB-269970 (10 and 30 mg/kg) 
significantly antagonised both amphetamine and ketamine-induced hyperactivity in 
mice; in addition to this, the effect on amphetamine-induced hyperactivity was not 
observed in 5-HT7 knock-out mice, suggesting that SB-269970 has good selectivity 
for the 5-HT7 receptor.  However, SB-269970 did not block ketamine-induced deficits 
in PPI (Galici et al., 2008).  PCP-induced deficits in PPI were reversed by SB-258741, 
an analogue of SB-269970 (Pouzet et al., 2002).  Conversely, in a more recent study it 
was shown that SB-269970 at 10 mg/kg did not reverse PCP-induced deficits in PPI 
(Semenova et al., 2008).  Therefore, there are conflicting results surrounding the 
effect of SB-269970 against PCP-induced deficits in PPI; however, we have 
demonstrated that SB-269970 at 3 and 10 mg/kg significantly reverses our sub-
chronic PCP-induced deficits in a reversal learning task of relevance to schizophrenia 
thus strengthening the argument for its importance in therapy of cognition in 
schizophrenia.  It has been hypothesised that 5-HT7 receptor antagonists may reverse 
PCP-induced deficits via the prevention of 5-HT and/or glutamate release (Semenova 
et al., 2008).  However, more research is needed to elucidate the cognitive-enhancing 
mechanisms of 5-HT7 receptor antagonists. 
   
Effect of SB-243213A 
SB-243213A is a selective 5-HT2C receptor antagonist (Bromidge et al., 2000).  5-
HT2C receptors are located in a variety of brain regions including the neocortex, 
amygdala, hippocampus, nucleus accumbens, substantia nigra and the ventral 
tegmental area (Pompeiano et al., 1994; Abramowski et al., 1995; Eberle-Wang et al., 
1997).  Antagonism at 5-HT2C receptors by various atypical antipsychotics (e.g. 
clozapine, risperidone, sertindole and ziprasidone; Roth et al., 2003) may play a role 
in their beneficial effects and their improved adverse effects profile (Meltzer, 1995; 
1999).  However, antagonism at the 5-HT2C receptor can increase food intake and 
body weight in rats (Bonhaus et al., 1997), thus this may not be an advantageous 
strategy for treatment in patients as weight gain is a major adverse effect and could 
affect compliance  (see Allison et al., 1999 for meta-analysis). 
SB-243213A is active in preclinical models of anxiety and has an improved 
anxiolytic profile compared with benzodiazepines (Wood et al., 2001; Blackburn et 
al., 2002).  SB-243213A may also have antidepressant-like activity as it increased 
deep slow wave sleep quantity with similar effect to paroxetine (Smith et al., 2002).  
There is limited data concerning the efficacy of SB-243213A in tests of cognition.  
The current data show that SB-243213A at 10.0 mg/kg selectively and significantly 
improved the PCP-induced deficit in the reversal phase of the task i.e. there were no 
effects on the initial phase or on total lever pressing.  This is supported by recent data 
showing improvements in spatial reversal learning by the 5-HT2C antagonist, 
SB242084 (Boulougouris et al., 2008), suggesting that the facilitatory effects of 5-
HT2C antagonists could be mediated by the orbitofrontal cortex (OFC) as this task 
(Boulougouris et al., 2007) and reversal learning within the attentional set shifting 
task (McAlonan and Brown, 2003) have been shown to be dependent on the OFC.  
The mechanism of the observed cognitive enhancement may be via increasing 
dopamine in the PFC.  5-HT2C receptor activation has been suggested to reduce 
dopamine release in the nucleus accumbens and prefrontal cortex (Di Matteo et al., 
2001).  The 5-HT2C antagonist, SB242084, enhances dopamine release in the nucleus 
accumbens (Di Matteo et al., 1999) and cortex (Gobert et al., 2000).   
 
Effect of buspirone and WAY-100635 
In the current study, the efficacy of buspirone to improve the PCP-induced reversal 
learning deficit was antagonised partially by the 5-HT1A antagonist, WAY-100635.  
There is evidence that 5-HT1A receptor density is abnormally high in the frontal 
cortices of patients with schizophrenia (Burnet et al., 1997) and a subsequent PET 
study has shown an increase in cortical 5-HT1A receptor binding in schizophrenia 
(Tauscher et al., 2002).  Post-mortem studies have also indicated abnormalities in 5-
HT1A receptor-mediated transmission in the frontal cortex of patients with 
schizophrenia (Sumiyoshi et al., 1996).  
Buspirone is a 5-HT1A receptor partial agonist with weak D2 receptor 
antagonist properties compared to typical antipsychotic drugs, with Ki values of 
20nM and 240nM respectively (Hamik et al., 1990).  WAY-100635 may not have 
fully antagonised the effects of buspirone as it is rapidly converted to its metabolite 1-
(2-pyrimidinyl)-piperazine (1-PP; Caccia et al., 1986), a potent α2-adrenoceptor 
antagonist, which is able to stimulate cortical dopamine release (Gobert et al., 1999). 
The effect of buspirone cannot be due to D2 blockade as haloperidol is ineffective in 
reversing the PCP-induced deficit (Abdul-Monim et al., 2006).   
It is important to highlight that WAY-100635 administered alone at both 0.3 
and 1.0 mg/kg did not improve the PCP-induced deficit.  This is in agreement with a 
study in mice using a novel object recognition task whereby WAY-100635 at 1.0 
mg/kg did not produce any improvement in the PCP-induced cognitive deficit 
(Hagiwara et al., 2008).  However, there are conflicting results surrounding the effects 
of WAY-100635 and other 5-HT1A receptor antagonists; Wedzony et al. (2000) 
reported that WAY-100135 attenuated the deficit induced by MK-801 in tests of 
working memory and selective attention in rats.  In addition, WAY-100635 has been 
shown to prevent learning deficits induced by blockade of AMPA receptors 
(Schiapparelli et al., 2006).  An explanation for the conflicting effects of WAY-
100635 and WAY-100135 could be due to the acute administration of MK-801 (an 
NMDA receptor antagonist) and NBQX (an AMPA receptor antagonist) in 
comparison to our sub-chronic PCP administration, and also, the aforementioned 
studies were performed in male Wistar rats compared to our female hooded-Lister rats.  
The antipsychotics clozapine, quetiapine, and ziprasidone have partial agonist 
properties at 5-HT1A receptors, like buspirone (Newman-Tancredi et al., 1998; 
Ichikawa et al., 2001).  There are conflicting preclinical results with 5-HT1A 
compounds with selective agonists, partial agonists, and antagonists all being 
highlighted as potential molecular targets for cognitive enhancement in schizophrenia 
(see Gray and Roth, 2007).  As previously mentioned there is a high concentration of 
5-HT1A receptors on cortical and hippocampal pyramidal neurons (Azmitia et al., 
1996).  There is also a population of 5-HT1A receptors on raphe neurons, where 5-
HT1A receptors function as somatodendritic autoreceptors providing inhibitory 
feedback control of 5-HT release (Barnes and Sharp, 1999).  It is thought that this is 
where the action of 5-HT1A antagonists is seen to improve cognition, while the 
beneficial effects on cognition in animal studies of 5-HT1A partial agonists are thought 
to be mediated via an action at pyramidal neurons (Roth et al., 2003; Schechter et al., 
2002).  In schizophrenic patients, the 5-HT1A agonist, tandospirone, has been shown 
to improve executive function and verbal memory when added on to ongoing typical 
antipsychotic treatment (Sumiyoshi et al., 2001). 
 Our results from the present study are supported by another investigation from 
our laboratory in a social interaction test (Snigdha and Neill, 2008a).  It was 
demonstrated that co-administration of WAY-100635 with aripiprazole, a partial 5-
HT1A agonist (Shapiro et al., 2003), successfully prevented the beneficial effects of 
aripiprazole in a social interaction model of negative symptoms.  It was suggested that 
5-HT1A receptor activation selectively augments cortical dopamine levels which 
results in improvement in the social behaviour deficits.  This suggestion is in 
agreement with a previous report by Ichikawa and colleagues (2001) suggesting that 
5-HT1A induced dopamine release in the mPFC may be the potential basis for the 
mechanism of action of at least some of the atypical antipsychotics.  Our previous 
results showing impaired cortical dopamine release in PCP treated rats supports this 
hypothesis.     
 
Conclusions 
Sub-chronic PCP induces a robust reversal learning deficit, which is selective for the 
reversal phase of the reversal learning task; this is of great relevance for cognition in 
schizophrenia and this paradigm is listed by TURNS as a relevant task.  SB-269970A, 
SB-243213A and buspirone attenuated the PCP-induced deficit, with WAY-100635 
partially antagonising the effect of buspirone. We have also demonstrated that when 
administered alone WAY-100635 did not improve the PCP-induced cognitive deficit. 
The current studies suggest possible mechanisms of action of antipsychotics and 
particularly implicate the role of 5-HT7, 5-HT2C and 5-HT1A receptors in the 
improvement of cognitive dysfunction of relevance to schizophrenia.  
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Tables and Figures 
 
Table 1  The experimental design for each drug study. 
Day 1 Day 2 Day 3 Day 4 Day 5 + 
Training 
session 
 
Drug test day, reversal 
test session. Data shown 
in results section 
Training 
session 
Reversal test 
session, drug-
free 
The cycle 
repeated as 
needed 
 
 
Table 2  The order of procedures and drug experiments post training. 
 
Week Experiment Cohort Procedure/treatment 
1 - 1 and 2 Sub-chronic PCP treatment 
2 - 1 and 2 7-day washout 
3 1 1 SB-269970A (1, 3, 10 mg/kg) 
4 2 2 SB-243213A (1, 3, 10 mg/kg) 
5 3 2 
Buspirone (0.15625, 0.3125, 
0.625 mg/kg) 
6 3 2 
Buspirone (0.3125 mg/kg) 
alone and with WAY-100635 
(0.3, 1 mg/kg) 
7 4 2 WAY-100635 (0.3, 1 mg/kg) 
 
 
 
 
 
 
 
 
 Fig 1a: Effect of the 5-HT7 receptor antagonist SB-269970A 
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 Fig 2a: Effect of the 5-HT2C receptor antagonist SB-243213A 
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Fig 2b 
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 Fig 3a: Effect of buspirone alone and in combination with WAY-100635 
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 Fig 4a: Effect of WAY-100635 
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 Figure Legends 
 
 
Figure 1: The influence of acute treatment with SB-269970A (1.0, 3.0, 10.0 mg/kg, 
i.p.) on the effect of sub-chronic PCP on performance of the initial and reversal phase 
of the reversal learning task (n=8-10). (a) Data are shown as the mean total number of 
lever presses, correct responses are shown as clear bars and incorrect responses are 
shown as shaded bars. (b) Data are shown as mean ± s.e.m. percent correct 
responding.  Paired t-tests showed a significant deficit in the reversal phase compared 
to the initial phase; ***P<0.001.  Post-hoc Dunnett’s t-test showed SB-269970A at 
3.0 and 10.0 mg/kg significantly improved responding compared to PCP + vehicle in 
the reversal phase; 
##
P<0.01. 
 
Figure 2: The influence of acute treatment with SB-243213A (1.0, 3.0, 10.0 mg/kg, 
i.p.) on the effect of sub-chronic PCP on performance of the initial and reversal phase 
of the reversal learning task (n=10). (a) Data are shown as the mean total number of 
lever presses, correct responses are shown as clear bars and incorrect responses are 
shown as shaded bars. (b) Data are shown as mean ± s.e.m. percent correct 
responding.  Paired t-tests showed a significant deficit in the reversal phase compared 
to the initial phase; **P<0.01, ***P<0.001.  Post-hoc Dunnett’s t-test showed SB-
243213A at 10.0 mg/kg significantly improved responding compared to PCP + 
vehicle in the reversal phase; 
#
P<0.05. 
 
Figure 3: The influence of buspirone (0.15625, 0.3125, 0.625 mg/kg, i.p.), and 
WAY-100635 (0.3, 1.0 mg/kg, i.p.) plus buspirone (0.3125 mg/kg, i.p.) on the effect 
of sub-chronic PCP on performance of the initial and reversal phase of the reversal 
learning task (8-20).  (a) Data are shown as the mean total number of lever presses, 
correct responses are shown as clear bars and incorrect responses are shown as shaded 
bars. (b)  Data are shown as mean ± s.e.m. percent correct responding.  A paired t-test 
showed a significant reduction in performance of the reversal phase compared with 
the initial phase; 
***
P<0.001, 
*P<0.05. Dunnett’s t-test showed significant 
improvement in responding compared to PCP + vehicle in the reversal phase at 
0.3125 mg/kg and 0.625 mg/kg; 
##
P<0.01.  Pretreatment with WAY-100635 at 0.3 
and 1.0 mg/kg did not reverse the effect of 0.3125 mg/kg buspirone (P=0.208 and 
P=0.082 respectively). 
 
Figure 4: The influence of WAY-100635 (0.3, 1.0 mg/kg, i.p.) alone on the effect of 
sub-chronic PCP on performance of the initial and reversal phase of the reversal 
learning task (n=8-10).  (a) Data are shown as the mean total number of lever presses, 
correct responses are shown as clear bars and incorrect responses are shown as shaded 
bars.  (b) Data are shown as mean ± s.e.m. percent correct responding.  A paired t-test 
showed a significant reduction in performance of the reversal phase compared with 
the initial phase; 
***
P<0.001, 
*P<0.05.  Dunnett’s t-test showed no significant 
improvement in responding compared to PCP + vehicle in the reversal phase at 0.3 
mg/kg and 1.0 mg/kg WAY-100635 (P=0.541 and P=0.422 respectively). 
